©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 111631
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.111631
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.111631
Figure 5 FBXO32 is the N6-methyladenosine modification target of IGF2BP3.
A: Heat map of differentially expressed genes identified by RNA sequencing (RNA-seq); B: Numbers of differentially expressed genes identified by RNA-seq; C: Numbers of N6-methyladenosine (m6A) peaks identified by methylated RNA immunoprecipitation sequencing (MeRIP-seq); D: M6A motifs identified by MeRIP-seq; E: Enriched regions of m6A peaks on messenger RNA (mRNA) identified by MeRIP-seq; F: Common genes between the small interfering RNA-negative control group and the small interfering RNA-IGF2BP3 group according to MeRIP-seq; G: Enriched regions of m6A peaks on mRNA identified by RNA immunoprecipitation sequencing (RIP-seq); H: Numbers of m6A peaks identified by RIP-seq; I: Genes identified by RIP-seq; J: Overlap analysis of genes identified by MeRIP-seq, RIP-seq, and RNA-seq; K: Analysis of the m6A site and its abundance on FBXO32 transcripts using Integrative Genomics Viewer software; L: Interaction between IGF2BP3 and FBXO32 as detected by RIP-quantitative polymerase chain reaction; M: Schematic of the wild-type FBXO32 sequence and the m6A site-mutated FBXO32 sequence fused to the luciferase reporter vector; N: Relative luciferase activity of wild-type and mutant (site 1427) FBXO32 upon IGF2BP3 overexpression; O: Relative luciferase activity of wild-type and mutant (site 1399) FBXO32 upon IGF2BP3 overexpression; P: Relative luciferase activity of wild-type and mutant (site 1493) FBXO32 upon IGF2BP3 overexpression. Data are shown as the mean ± SD. aP < 0.05. bP < 0.01. siNC: Small interfering RNA-negative control; siIGF2BP3: Small interfering RNA-IGF2BP3; DEG: Differentially expressed gene; m6A: N6-methyladenosine; CDS: Coding sequence; UTR: Untranslated regions; RIP-seq: RNA immunoprecipitation sequencing; MeRIP-seq: Methylated RNA immunoprecipitation sequencing; RNA-seq: RNA sequencing; WT: Wild type; Mut: Mutant; NS: Not significant.
- Citation: Si Y, Tian B, Zhang R, Xuan MD, Liu KY, Jiao J, Han SS, Li HF, Hu YH, Zhao HY, He WJ, Wang J, Liu T, Yu WF. IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression. World J Gastroenterol 2025; 31(46): 111631
- URL: https://www.wjgnet.com/1007-9327/full/v31/i46/111631.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i46.111631